Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 7/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520367 | 0.96 | SOAT1 (0.54) | SOAT1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL5469635 | 0.91 | SOAT1 (0.59) | SOAT1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL14520325 | 0.89 | SOAT1 (0.51) | SOAT1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL5483383 | 0.87 | SOAT1 (0.60) | SOAT1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL4876624 | 0.87 | SOAT1 (0.62) | SOAT1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL14520369 | 0.87 | SOAT1 (0.55) | SOAT1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL5466017 | 0.86 | SOAT1 (0.59) | SOAT1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL14520366 | 0.85 | SOAT1 (0.49) | SOAT1HTR1ATSHR | |
| SCHEMBL5473580 | 0.85 | SOAT1 (0.56) | SOAT1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL14520326 | 0.84 | SOAT1 (0.62) | SOAT1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | SOAT1 1040/4885HTR1A 1323/4885ADRA1D 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.